Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • McKesson to pay $37...

    McKesson to pay $37 million to settle West Virginia opioid lawsuit

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-05T09:00:48+05:30  |  Updated On 5 May 2019 9:00 AM IST
    McKesson to pay $37 million to settle West Virginia opioid lawsuit




    Under the agreement, McKesson will pay $14.5 million this year and another $4.5 million annually for the next five years. It said the money will go toward funding initiatives to combat the epidemic.

    New Delhi: Drug distributor McKesson Corp has agreed to pay $37 million to resolve a lawsuit by the state of West Virginia alleging it helped fuel a U.S. opioid epidemic by failing to stop suspicious orders of painkillers by pharmacies in the state.

    The settlement announced by West Virginia Attorney General Patrick Morrisey on Thursday came in one of the hundreds of similar lawsuits by states and local governments against McKesson and other distributors over their roles in the opioid crisis.

    The settlement was the largest that a distributor has agreed with a state in the litigation. West Virginia previously settled similar cases against other distributors, including Cardinal Health Inc and Amerisource Bergen Corp.

    Under the agreement, McKesson will pay $14.5 million this year and another $4.5 million annually for the next five years. It said the money will go toward funding initiatives to combat the epidemic.

    Read Also: Trump sets speech on opioid fight after drug distributor, executives face criminal charges

    McKesson did not admit wrongdoing, and in a statement said it continued to deny the allegations.

    "McKesson is committed to working with others to end this national crisis, however, and is pleased that the settlement provides funding toward initiatives intended to address the opioid epidemic," McKesson said.

    Opioids, including prescription painkillers, heroin and fentanyl, were involved in a record 47,600 overdose deaths in 2017, according to the U.S. Centers for Disease Control and Prevention.

    The epidemic has prompted lawsuits by state and local governments accusing drug manufacturers like Purdue Pharma of deceptively marketing opioids, and distributors like McKesson of failing to detect the diversion of the drugs for illicit purposes.

    Morrisey sued McKesson in 2016 in Boone County Circuit Court, accusing it of putting profits over the welfare of the state's citizens by failing to investigate, report and stop suspicious orders of opioids by pharmacies.

    The lawsuit alleged that from 2007 to 2012, McKesson distributed high quantities of opioids to pharmacies and drug stores in the state.

    In Boone County alone, the company distributed 1.29 million doses of hydrocodone and oxycodone, enough for each of its 24,629 residents to receive 52.3 doses, the complaint said.

    West Virginia in total has recovered more than $84 million in opioid-related lawsuits against drug distributors, including $20 million from Cardinal Health Inc and $16 million from AmerisourceBergen.

    McKesson in 2017 agreed to pay $150 million to resolve a federal investigation by the U.S. Drug Enforcement Administration into whether it failed to report suspicious orders of addictive painkillers.



    Amerisource Bergen CorpBostonCardinal healthCardinal Health IncDrug distributor McKesson CorpfentanylGeneral Patrick MorriseyHealthcareheroinhydrocodoneMcKessonopioidopioid crisisoxycodonepainkillersPurdue PharmaWest VirginiaWest Virginia Attorney
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok